Aspire-Lakewood Holdings, Inc. (ASBP) Stock

About Aspire-Lakewood Holdings, Inc.

Aspire Biopharma Holdings, Inc. is an emerging pharmaceutical enterprise dedicated to pioneering and commercializing innovative sublingual drug delivery systems within the United States. Its flagship product, Instaprin, is an advanced sublingual aspirin formulation known for being soluble, pH neutral, and rapidly absorbed, making it effective for both cardiovascular emergencies and general pain management. The company is diligently developing a diverse pipeline of orally dissolving formulations. This includes a melatonin-based sleep aid, essential vitamins (D, E, and K), testosterone, and semaglutide. Furthermore, Aspire Biopharma is extending its sublingual development efforts to various therapeutic areas, such as anti-nausea treatments, antipsychotic medications, erectile dysfunction drugs, and seizure control therapies, among others. They are also exploring caffeine products, including a formulation for a single-dose sublingual pre-workout supplement. Established in 2021, the firm's main operational base is situated in Estero, Florida.

Aspire-Lakewood Holdings, Inc. is led by CEO Kraig T. Higginson, employs 2 people, headquartered in US, publicly traded since 2025.

Aspire-Lakewood Holdings, Inc. (ASBP) stock trades at $8.80 with a market capitalization of $1.02M. The stock is valued at a negative price-to-earnings (P/E) ratio of -1.09, reflecting a net loss over the last twelve months, price-to-book of 0.78, price-to-sales of 10.37. Over the past 52 weeks the stock has ranged between $0.11 and $562.80, and currently trades 98.4% below its 52-week high.

On profitability, Aspire-Lakewood Holdings, Inc. generates a return on equity (ROE) of 199.43% (not meaningful, as shareholders' equity is negative), return on capital employed of -59.81%, a net profit margin of -340.40%.

Official website: aspirebiolabs.com

Aspire-Lakewood Holdings, Inc. by the numbers, 2021–2025

Between 2021 and 2025 Aspire-Lakewood Holdings, Inc. reported revenue of $0 rising to $0. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit was $-24.0M in 2025.

The most recent net margin is -340.40%. On a trailing twelve-month basis to Jun '26, revenue is $0 and net profit $-11.0M.

Borrowings stand at $1.0M, cash on hand is $12.0M, cash from operations was $-5.0M in the latest year, positive in 0 of the last 5.

Return on equity has averaged 117.8% over five years, and was 400.0% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Aspire-Lakewood Holdings, Inc. (ASBP) — frequently asked questions